Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral

Chardan Capital Markets analyst Keay Nakae downgraded NeuBase Therapeutics (NASDAQ: NBSE) from Buy to Neutral.

The analyst comments "We believe that the company's proprietary PATrOL design platform can be thought of as a toolkit to address a number of the known challenges with gene medicine payloads. That said, the company has yet to announce any preclinical data regarding its gene editing capabilities. Hence, we find it impossible to construct an appropriate valuation model for the company at this time."

For an analyst ratings summary and ratings history on NeuBase Therapeutics click here. For more ratings news on NeuBase Therapeutics click here.

Shares of NeuBase Therapeutics closed at $0.27 yesterday.

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Westamerica Bancorp (WABC) PT Lowered to $50 at Piper Sandler
• London Stock Exchange Group Plc. (LSEG:LN) (LNSTY) PT Raised to GBP88 at HSBC